If you have any questions or concerns please contact Ken Baker at 573-884-6479
Through the clinical trials program at Ellis Fischel Cancer Center, patients might have access to treatments years before they become widely available. "The reason we are where we are today is because of clinical trials," said C. Daniel Kingsley, MD, FACP, Ellis Fischel oncologist and director of the trials program. "For some patients, these treatments are game changers because having that access a year or even two years before anyone else can make a huge difference for a cancer patient. You are giving them a head start." For Dr. Kingsley, imagining a world without cancer means a future where treatments for each patient become even more personalized.
"I can see a future where we can examine your specific cancer, then examine its gene expression and tailor the treatment specifically to the genetic makeup. Maybe it’s a vaccine or maybe it’s antibodies, but we are getting closer to a world of personalized treatments." Even if we never reach a perfect world without cancer, Dr. Kingsley said he can envision a world where the survival rates for cancer improve and treatments become less toxic to the body. Right now, he’s proud of the work going on at Ellis Fischel.
"We have an incredible amount of brain power under one roof to create the best treatment plan for each patient," Kingsley said. "Not only that, but we are collaborating with researchers across the University of Missouri campus to better understand the how cancer behaves and reacts to treatments."
Clinical trials are research studies that involve people. They are the final step in a long process that begins with research in a lab and animal testing. Many treatments used today are the result of past clinical trials.
Ellis Fischel Cancer Center physicians and staff ensure that all of our patients receive the best care. This means if we ask you or a loved one to participate in a clinical trial, we have good reason to believe that the new treatment(s) will help and we see promise and potential in the new treatment options. These new treatments could become the new standard of care and we want only the best for our patients.
A011106: Alternate approaches for clinical stage II or Ill Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal women: A Phase Ill Study. NCT01953588
S1207: Phase III Randomized, Controlled-Placebo Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy+/-One Year of Everolimus in Patients w/High-Risk, Hormone Receptor-Positive & HER2/neu Negative Breast Cancer. NCT01674140
E2112 A Randomized Phase III Trial of Endocrine Therapy + Entinostat/Placebo in Postmenopausal Patients w/ Hormone Receptor-Positive Advanced Breast Cancer. NCT02115282
ACCRU RU0112011/Eisai Inc-E7389-A001 -303: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-line Therapy for locally Recurrent or Metastatic Breast Cancer. NCT02037529
NGR-BR003: Phase Ill Dose-Dense Adjuvant AC followed by weekly Taxol+/-Carboplatin for node-positive or high risk nose-neg HER2-neg, ER-neg, and PR-neg invasive (unilateral) BC NCT02488967
A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer NCT02750826
- SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 w/Androgen Deprivation Therapy + Bicalutamide in Patients w/Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer. NCT01809691
Renal (Kidney) Cancer
- E2810: Randomized, Double-Blind Phase Ill Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy NCT01575548
Gynecological Oncology (GYN)
GOG Foundation 3005/AbbVie M13-694: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects with Previously Untreated Stages Ill or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02470585
NRG-GY005: Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or SOC Chemotherapy in Recurrent Platinum Resistant/refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02502266
Janssen OVC-3006: A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL with DOXIL Monotherapy for the treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT01846611
Head and Neck, Supportive Care
Gilead Sciences Inc GS US 339 0102: Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics ofGS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies *(Now open only for Chronic Lymphocytic Leukemia that has recurred after ibrutinib and/or idelalisib therapy) NCT# 01799889
Non-Small Cell Lung Cancer
- SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for 2nd line Therapy of Squamous Cell Lung Cancer (Lung MAP). NCT02154490
- S1400B: A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
- S1400D: A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map sub-Study)
- S1400I: A Phase III Randomized Study of Nivolumab plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung cancer and No Matching Biomarker (Lung-Map Sub-Study)
- A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) NCT02194738
- E4512: Phase III Crizotinib vs Placebo for Adjuvant Therapy of ALK+ NSCLC NCT02201992
- A081105: Phase III Erlotinib vs Placebo Adjuvant Therapy for EGFR Mutant NSCLC - NCT02193282
- EA5142: Phase III Nivolumab vs Observation Adjuvant Therapy for EGFR/ALK wildtype (if non-squamous) or squamous NSCLC NCT02595944
Celgene-CC 5013-NHL-008: Phase 3b Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. NCT 01996865
Genentech G029834 Harmony :A Phase lb/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (currently enrolling only to Follicular Lymphoma cohorts) NCT 02600897
NCl-MATCH/EAY131: Molecular Analysis for Therapy Choice - This phase II trial studies how well treatment that is directed by genetic testing work in patients with lymphomas that have progressed following at least one line of standard treatment or for which no standard treatment exists. NCT02465060
E1A11: Randomized Phase Ill Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) NCT01863550
- NCl-MATCH/EAY131 Molecular Analysis for Therapy Choice - This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors that have progressed following at least one line of standard treatment or for which no standard treatment approach exists. NCT02465060